Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 160

1.

Multiple Endocrine Neoplasia Type 2B Presents Early in Childhood but Often Is Undiagnosed for Years.

Makri A, Akshintala S, Derse-Anthony C, Widemann B, Stratakis CA, Glod J, Lodish M.

J Pediatr. 2018 Dec;203:447-449. doi: 10.1016/j.jpeds.2018.08.022. Epub 2018 Oct 9.

PMID:
30314660
2.

Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.

Rauen KA, Schoyer L, Schill L, Stronach B, Albeck J, Andresen BS, Cavé H, Ellis M, Fruchtman SM, Gelb BD, Gibson CC, Gripp K, Hefner E, Huang WYC, Itkin M, Kerr B, Linardic CM, McMahon M, Oberlander B, Perlstein E, Ratner N, Rogers L, Schenck A, Shankar S, Shvartsman S, Stevenson DA, Stites EC, Stork PJS, Sun C, Therrien M, Ullian EM, Widemann BC, Yeh E, Zampino G, Zenker M, Timmer W, McCormick F.

Am J Med Genet A. 2018 Dec;176(12):2924-2929. doi: 10.1002/ajmg.a.40632. Epub 2018 Oct 10.

PMID:
30302932
3.

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1.

Isakson SH, Rizzardi AE, Coutts AW, Carlson DF, Kirstein MN, Fisher J, Vitte J, Williams KB, Pluhar GE, Dahiya S, Widemann BC, Dombi E, Rizvi T, Ratner N, Messiaen L, Stemmer-Rachamimov AO, Fahrenkrug SC, Gutmann DH, Giovannini M, Moertel CL, Largaespada DA, Watson AL.

Commun Biol. 2018 Oct 2;1:158. doi: 10.1038/s42003-018-0163-y. eCollection 2018.

4.

Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.

Parker VER, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, De Silva L, Sapp JC, Andrews K, Bardou M, Chen KY, Darling TN, Gautier E, Goldspiel BR, Hadj-Rabia S, Harris J, Kounidas G, Kumar P, Lindhurst MJ, Loffroy R, Martin L, Phan A, Rother KI, Widemann BC, Wolters PL, Coubes C, Pinson L, Willems M, Vincent-Delorme C; PROMISE Working Group, Vabres P, Semple RK, Biesecker LG.

Genet Med. 2018 Oct 1. doi: 10.1038/s41436-018-0297-9. [Epub ahead of print]

PMID:
30270358
5.

Pheochromocytoma in Children and Adolescents With Multiple Endocrine Neoplasia Type 2B.

Makri A, Akshintala S, Derse-Anthony C, Del Rivero J, Widemann B, Stratakis CA, Glod J, Lodish M.

J Clin Endocrinol Metab. 2019 Jan 1;104(1):7-12. doi: 10.1210/jc.2018-00705.

6.

Clinical trial design for cutaneous neurofibromas.

Cannon A, Jarnagin K, Korf B, Widemann BC, Casey D, Ko HS, Blakeley JO, Verma SK, Pichard DC.

Neurology. 2018 Jul 10;91(2 Supplement 1):S31-S37. doi: 10.1212/WNL.0000000000005790.

PMID:
29987133
7.

Creating a comprehensive research strategy for cutaneous neurofibromas.

Blakeley JO, Wolkenstein P, Widemann BC, Lee J, Le LQ, Jackson R, Stathis M, Verma SK.

Neurology. 2018 Jul 10;91(2 Supplement 1):S1-S4. doi: 10.1212/WNL.0000000000005789.

PMID:
29987129
8.

Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques.

Nellan A, McCully CML, Cruz Garcia R, Jayaprakash N, Widemann BC, Lee DW, Warren KE.

Blood. 2018 Aug 9;132(6):662-666. doi: 10.1182/blood-2018-05-846428. Epub 2018 Jun 28. No abstract available.

PMID:
29954750
9.

Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1.

Gross AM, Singh G, Akshintala S, Baldwin A, Dombi E, Ukwuani S, Goodwin A, Liewehr DJ, Steinberg SM, Widemann BC.

Neuro Oncol. 2018 Nov 12;20(12):1643-1651. doi: 10.1093/neuonc/noy067.

PMID:
29718344
10.

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.

Chuk MK, Widemann BC, Minard CG, Liu X, Kim A, Bernhardt MB, Kudgus RA, Reid JM, Voss SD, Blaney S, Fox E, Weigel BJ.

Pediatr Blood Cancer. 2018 Aug;65(8):e27077. doi: 10.1002/pbc.27077. Epub 2018 Apr 25.

PMID:
29693796
11.

2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Fisher MJ, Belzberg AJ, de Blank P, De Raedt T, Elefteriou F, Ferner RE, Giovannini M, Harris GJ, Kalamarides M, Karajannis MA, Kim A, Lázaro C, Le LQ, Li W, Listernick R, Martin S, Morrison H, Pasmant E, Ratner N, Schorry E, Ullrich NJ, Viskochil D, Weiss B, Widemann BC, Zhu Y, Bakker A, Serra E.

Am J Med Genet A. 2018 May;176(5):1258-1269. doi: 10.1002/ajmg.a.38675.

PMID:
29681099
12.

Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2.

Huang V, Bergner AL, Halpin C, Merker VL, Sheridan MR, Widemann BC, Blakeley JO, Plotkin SR.

Otol Neurotol. 2018 Jun;39(5):632-638. doi: 10.1097/MAO.0000000000001781.

PMID:
29649040
13.

The Relationship Between Heart Rate Variability, Psychological Flexibility, and Pain in Neurofibromatosis Type 1.

Allen TM, Struemph KL, Toledo-Tamula MA, Wolters PL, Baldwin A, Widemann B, Martin S.

Pain Pract. 2018 Nov;18(8):969-978. doi: 10.1111/papr.12695. Epub 2018 Apr 23.

PMID:
29570943
14.

The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.

Higham CS, Dombi E, Rogiers A, Bhaumik S, Pans S, Connor SEJ, Miettinen M, Sciot R, Tirabosco R, Brems H, Baldwin A, Legius E, Widemann BC, Ferner RE.

Neuro Oncol. 2018 May 18;20(6):818-825. doi: 10.1093/neuonc/noy013.

PMID:
29409029
15.
16.

Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.

Kraft IL, Akshintala S, Zhu Y, Lei H, Derse-Anthony C, Dombi E, Steinberg SM, Lodish M, Waguespack SG, Kapustina O, Fox E, Balis FM, Merino MJ, Meltzer PS, Glod JW, Shern JF, Widemann BC.

Clin Cancer Res. 2018 Feb 15;24(4):753-765. doi: 10.1158/1078-0432.CCR-17-2101. Epub 2017 Nov 29.

PMID:
29187393
17.

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors.

Higham CS, Steinberg SM, Dombi E, Perry A, Helman LJ, Schuetze SM, Ludwig JA, Staddon A, Milhem MM, Rushing D, Jones RL, Livingston M, Goldman S, Moertel C, Wagner L, Janhofer D, Annunziata CM, Reinke D, Long L, Viskochil D, Baker L, Widemann BC.

Sarcoma. 2017;2017:8685638. doi: 10.1155/2017/8685638. Epub 2017 Sep 12.

18.

Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future.

Reilly KM, Kim A, Blakely J, Ferner RE, Gutmann DH, Legius E, Miettinen MM, Randall RL, Ratner N, Jumbé NL, Bakker A, Viskochil D, Widemann BC, Stewart DR.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx124. Review.

19.

Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods.

Cai W, Steinberg SM, Bredella MA, Basinsky G, Somarouthu B, Plotkin SR, Solomon J, Widemann BC, Harris GJ, Dombi E.

Acad Radiol. 2018 Feb;25(2):144-152. doi: 10.1016/j.acra.2017.09.004. Epub 2017 Oct 31.

PMID:
29097016
20.

Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.

Ramsey LB, Balis FM, O'Brien MM, Schmiegelow K, Pauley JL, Bleyer A, Widemann BC, Askenazi D, Bergeron S, Shirali A, Schwartz S, Vinks AA, Heldrup J.

Oncologist. 2018 Jan;23(1):52-61. doi: 10.1634/theoncologist.2017-0243. Epub 2017 Oct 27.

Supplemental Content

Loading ...
Support Center